Nabriva to Present at the Rodman & Renshaw 18th Annual

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Nabriva to Present at the Rodman & Renshaw 18th Annual Global Investment Conference

VIENNA, Austria and KING OF PRUSSIA, Pa., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ: NBRV ), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that Dr. Colin Broom, Nabriva’s Chief Executive Officer, will present at the Rodman & Renshaw 18th Annual Global Investment Conference on Monday, September 12, 2016 at 10:25a.m. Eastern Time in New York, NY.  Dr. Broom will provide a Nabriva overview and business update.

The presentation will be webcast live and may be accessed by visiting the "Investors" section of Nabriva’s web site under the "Events and Presentations" tab at http://investors.nabriva.com/ . A replay the webcast will be available for 90 days.

About Nabriva Therapeutics AG

Nabriva Therapeutics is a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics. Nabriva's medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate. Nabriva's lead pleuromutilin product candidate, lefamulin, is being developed to be the first systemically available pleuromutilin for human use and is the first new class of antibiotic to reach late stage clinical development for community-acquired bacterial pneumonia (CABP) in over a decade. Nabriva believes lefamulin is well positioned for use as a first-line empiric monotherapy for the treatment of moderate to severe CABP due to its novel mechanism of action, targeted spectrum of activity, resistance profile, achievement of substantial drug concentration in lung tissue and fluid, oral and IV formulations and favorable tolerability profile. Nabriva also intends to further pursue the development of lefamulin for additional indications, including the treatment of acute bacterial skin and skin structure infections, and is developing a formulation of lefamulin appropriate for pediatric use.

Nabriva owns exclusive, worldwide rights to lefamulin, which is protected by composition of matter patents issued in the United States, Europe and Japan.

Forward Looking Statements

Any statements in this press release about future expectations, plans and prospects for Nabriva, including but not limited to statements about the composition of its Supervisory Board, development of Nabriva’s product candidates, such as plans for the design, conduct and timelines of Phase 3 clinical trials of lefamulin for CABP, the clinical utility of lefamulin for CABP and Nabriva’s plans for filing of regulatory approvals and efforts to bring lefamulin to market, the development of lefamulin for additional indications, the development of additional formulations of lefamulin, plans to pursue research and development of other product candidates and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and conduct of clinical trials, availability and timing of data from clinical trials, whether results of early clinical trials or trials in different disease indications will be indicative of the results of ongoing or future trials, uncertainties associated with regulatory review of clinical trials and applications for marketing approvals, the availability or commercial potential of product candidates including lefamulin for use as a first-line empiric monotherapy for the treatment of moderate to severe CABP, the sufficiency of cash resources and need for additional financing and such other important factors as are set forth under the caption "Risk Factors" in Nabriva’s annual report on Form 20-F as filed with the United States Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Nabriva’s views as of the date of this release. Nabriva anticipates that subsequent events and developments will cause its views to change. However, while Nabriva may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Nabriva’s views as of any date subsequent to the date of this release.

Contact: Will Sargent Nabriva Therapeutics AG William.Sargent@nabriva.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 175

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 205

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 286

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 327

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 207

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 221

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 330

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 299

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 287

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 264

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading

Top 5 Most Recently Viewed Articles

Challenges Ahead for Beyond Meat Despite Steady Price Target

Updated Category News Views 126

Beyond Meat's Current Stock Evaluation Piper Sandler continues to maintain its underweight rating on Beyond Meat Inc. (NASDAQ: BYND), keeping a price target steadfast at $3.00. This decision follows insights gained from their extensive Teen Survey, which engaged around 13,500 participants about their views on plant-based meat products. Survey Insights and Teen Trends The...

Continue Reading
LaFleur Minerals Paves the Way for Gold Mill Restart with Drilling

Updated Category News Views 194

LaFleur Minerals Focuses on Gold Production Enhancement Lafleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) is making significant strides towards initiating gold production with the recent commencement of a confirmation drilling program at its Swanson Gold Deposit. Located in a region rich in mineral resources, this initiative aims to gather essential data for a Preliminary...

Continue Reading
Understanding the Class Action Involving Integral Ad Science

Updated Category News Views 187

Important Update for Integral Ad Science Investors Integral Ad Science Holding Corp. (NASDAQ: IAS) investors should be aware of a crucial class action lawsuit. Legal representation is being provided by Kirby McInerney LLP, a trusted law firm, assisting affected individuals in navigating their rights and interests concerning this matter. Understanding the Class Action...

Continue Reading
Netformx and Ingram Micro Launch API to Enhance Sales Insights

Updated Category News Views 135

Netformx and Ingram Micro Team Up for an Innovative API Solution In an exciting partnership, Netformx, an industry leader in automation tools for IT solution providers, announced a new API collaboration with Ingram Micro. This integration aims to provide channel partners with a seamless view of their sales pipelines, enabling improved planning and enhanced deal...

Continue Reading
Purpose Healing Center Marks 8 Years of Service and Commitment

Updated Category News Views 185

Purpose Healing Center Marks 8 Years of Impact in Behavioral Health Purpose Healing Center, a prominent behavioral health and substance use treatment provider based in Scottsdale, Arizona, proudly celebrates its eighth anniversary of serving AHCCCS members statewide. The organization has made significant strides toward enhancing access to critical mental health services...

Continue Reading